[go: up one dir, main page]

BR9812001A - Composição farmacêutica para combinação de descongestionante piperidinoalcanol - Google Patents

Composição farmacêutica para combinação de descongestionante piperidinoalcanol

Info

Publication number
BR9812001A
BR9812001A BR9812001-8A BR9812001A BR9812001A BR 9812001 A BR9812001 A BR 9812001A BR 9812001 A BR9812001 A BR 9812001A BR 9812001 A BR9812001 A BR 9812001A
Authority
BR
Brazil
Prior art keywords
formulation
amount
weight
carrier material
basic carrier
Prior art date
Application number
BR9812001-8A
Other languages
English (en)
Inventor
David Douglas Maclaren
John Robert Lefler
Sharon Kay Minish
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25443270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of BR9812001A publication Critical patent/BR9812001A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO FARMACêUTICA PARA COMBINAçãO DE DESCONGESTIONANTE PIPERIDINOALCANOL"<D>. A presente invenção provê uma composição farmacêutica na forma de um comprimido de dupla camada compreendendo: (a) uma primeira zona distinta feita com a Formulação A, que compreende uma quantidade terapeuticamente eficaz como descongestionante de um medicamento simpatomimético, ou de um sal farmaceuticamente aceitável do mesmo, em uma quantidade de cerca de 18% a cerca de 39% em peso da formulação (A), e um primeiro material básico carreador, o primeiro material básico carreador compreendendo uma mistura de: (i) cera de carnaúba em uma quantidade de cerca de 59% a cerca de 81% em peso da formulação (A); e (ii) um antiaderente adequado em uma quantidade de cerca de 0,25% a cerca de 2,00% em peso da formulação (A); em que o referido primeiro material básico carreador provê uma liberação sustentada do medicamento simpatomimético; e (b) uma segunda zona distinta feita com a formulação (B) que compreende uma quantidade terapeuticamente eficaz como anti-histamínico de um piperidinoalcanol, ou de um sal farmaceuticamente aceitável do mesmo, em uma quantidade de cerca de 15% a cerca de 30% em peso da Formulação (B) e de um segundo material básico carreador, o segundo material básico carreador compreendendo uma mistura de: (i) um diluente celulósico em uma quantidade de cerca de 27% a cerca de 73% em peso da Formulação (B); (ii) amido pré-gelatinizado em uma quantidade de cerca de 15% a cerca de 30% em peso da Formulação (B); (iii) um desintegrante adequado em uma quantidade de cerca de 0,25% a cerca de 6,0% em peso da Formulação (B); e (iv) um lubrificante adequado em uma quantidade de cerca de 0,25% a cerca de 2,00% em peso da Formulação (B); em que o segundo material básico carreador provê uma liberação imediata do piperidinoalcanol ou de seu sal farmaceuticamente aceitável.
BR9812001-8A 1997-08-26 1998-07-21 Composição farmacêutica para combinação de descongestionante piperidinoalcanol BR9812001A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92015897A 1997-08-26 1997-08-26
PCT/US1998/015237 WO1999009957A1 (en) 1997-08-26 1998-07-21 Pharmaceutical composition for combination of piperidinoalkanol-decongestant

Publications (1)

Publication Number Publication Date
BR9812001A true BR9812001A (pt) 2000-09-26

Family

ID=25443270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812001-8A BR9812001A (pt) 1997-08-26 1998-07-21 Composição farmacêutica para combinação de descongestionante piperidinoalcanol

Country Status (30)

Country Link
US (1) US6039974A (pt)
EP (1) EP0998272B1 (pt)
JP (1) JP4344405B2 (pt)
KR (1) KR100514264B1 (pt)
CN (1) CN1159012C (pt)
AR (1) AR013947A1 (pt)
AT (1) ATE238773T1 (pt)
AU (1) AU725811B2 (pt)
BR (1) BR9812001A (pt)
CZ (1) CZ295461B6 (pt)
DE (1) DE69814086T2 (pt)
DK (1) DK0998272T3 (pt)
EE (1) EE04294B1 (pt)
ES (1) ES2192781T3 (pt)
HU (1) HU224921B1 (pt)
ID (1) ID22891A (pt)
IL (1) IL133420A (pt)
NO (1) NO318246B1 (pt)
NZ (1) NZ501248A (pt)
OA (1) OA11285A (pt)
PL (1) PL192079B1 (pt)
PT (1) PT998272E (pt)
RU (1) RU2207879C2 (pt)
SI (1) SI0998272T1 (pt)
SK (1) SK283803B6 (pt)
TR (1) TR200000517T2 (pt)
TW (1) TW570812B (pt)
UA (1) UA60335C2 (pt)
WO (1) WO1999009957A1 (pt)
ZA (1) ZA987552B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0766668B1 (en) * 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
IL158334A0 (en) * 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
ATE365544T1 (de) * 2002-04-04 2007-07-15 Reddys Lab Ltd Dr Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
ES2239554T1 (es) * 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
JP2007517050A (ja) * 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
CN104788328B (zh) 2004-06-24 2017-09-12 沃泰克斯药物股份有限公司 Atp‑结合弹夹转运蛋白的调控剂
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
US20080095846A1 (en) * 2004-11-04 2008-04-24 Gour Mukherji Pharmaceutical compositions of antihistamine and decongestant
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20080118554A1 (en) * 2006-06-30 2008-05-22 Limor Ari-Pardo Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20080085311A1 (en) * 2006-10-05 2008-04-10 Tripathi Sanjay S Antihistamine-decongestant combinations
ES2639854T3 (es) * 2007-02-01 2017-10-30 Takeda Pharmaceutical Company Limited Preparación de comprimidos sin causar problemas de fabricación de comprimidos
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
WO2008114280A1 (en) * 2007-03-21 2008-09-25 Lupin Limited Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
CA2718697C (en) 2008-03-21 2014-09-23 Mylan Pharmaceuticals, Inc. Extended release formulation containing a wax
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN102271672B (zh) * 2008-11-19 2015-02-04 梅里亚有限公司 用于治疗寄生物感染的包含单独的或与甲脒组合的1-芳基吡唑的组合物
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20120100221A1 (en) 2009-06-02 2012-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP2019218313A (ja) * 2018-06-21 2019-12-26 沢井製薬株式会社 プソイドエフェドリン又はその薬学的に許容される塩を含有する徐放製剤
WO2022261610A1 (en) * 2021-06-07 2022-12-15 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3806526A (en) * 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
EP0111114A3 (de) * 1982-11-06 1985-10-09 Telefonbau und Normalzeit GmbH Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
JPH0196920A (ja) * 1987-10-09 1989-04-14 Fujitsu Ltd ウエーハの識別方法
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
ZA90341B (en) * 1989-01-23 1990-10-31 Merrell Dow Pharma Liquid pharmaceutical composition for piperidinoalkanol derivatives
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
DK0616524T3 (da) * 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1993023047A1 (en) * 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
DE701443T1 (de) * 1992-08-03 1997-01-30 Georgetown University, Washington, D.C. Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
EP1369409B1 (en) * 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
EP0766668B1 (en) * 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
JP3638289B2 (ja) * 1996-08-16 2005-04-13 シェーリング コーポレイション ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
JPH10114655A (ja) * 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
JP2001524108A (ja) * 1997-04-30 2001-11-27 ワーナー−ランバート・カンパニー 局所経鼻抗炎症組成物
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
JP2001527023A (ja) * 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
CZ293666B6 (cs) * 1997-08-14 2004-06-16 Aventis Pharmaceuticals Inc. Farmaceutický prostředek se zvýšenou biodostupností antihistaminika a použití
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Also Published As

Publication number Publication date
JP4344405B2 (ja) 2009-10-14
NO20000932D0 (no) 2000-02-25
IL133420A (en) 2004-07-25
CN1159012C (zh) 2004-07-28
PL192079B1 (pl) 2006-08-31
HUP0002183A2 (hu) 2000-11-28
CZ295461B6 (cs) 2005-08-17
EE04294B1 (et) 2004-06-15
TW570812B (en) 2004-01-11
OA11285A (en) 2003-07-29
US6039974A (en) 2000-03-21
NZ501248A (en) 2001-06-29
NO20000932L (no) 2000-04-18
NO318246B1 (no) 2005-02-21
PL337348A1 (en) 2000-08-14
CZ458199A3 (cs) 2000-05-17
HK1025904A1 (en) 2000-12-01
JP2002511102A (ja) 2002-04-09
ES2192781T3 (es) 2003-10-16
HU224921B1 (hu) 2006-04-28
HUP0002183A3 (en) 2000-12-28
AU8582098A (en) 1999-03-16
AU725811B2 (en) 2000-10-19
SK177799A3 (en) 2000-07-11
ATE238773T1 (de) 2003-05-15
KR20010013543A (ko) 2001-02-26
EE200000098A (et) 2000-12-15
CN1268050A (zh) 2000-09-27
ZA987552B (en) 1999-02-26
AR013947A1 (es) 2001-01-31
IL133420A0 (en) 2001-04-30
PT998272E (pt) 2003-09-30
DE69814086D1 (de) 2003-06-05
SK283803B6 (sk) 2004-02-03
SI0998272T1 (en) 2003-12-31
DK0998272T3 (da) 2003-08-25
TR200000517T2 (tr) 2000-08-21
ID22891A (id) 1999-12-16
EP0998272B1 (en) 2003-05-02
EP0998272A1 (en) 2000-05-10
KR100514264B1 (ko) 2005-09-15
RU2207879C2 (ru) 2003-07-10
DE69814086T2 (de) 2004-04-08
WO1999009957A1 (en) 1999-03-04
UA60335C2 (uk) 2003-10-15

Similar Documents

Publication Publication Date Title
BR9812001A (pt) Composição farmacêutica para combinação de descongestionante piperidinoalcanol
Coukell et al. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
AU610178B2 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
BR0012869A (pt) Forma de dosagem farmacêutica de componentes múltiplos
EP0316434B1 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
BR0211198A (pt) Composições farmacêuticas e seu uso
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
BR0110914A (pt) Composição farmacêutica lìquida, conjugado, processo para preparação e utilização de uma composição, processo para o tratamento e prevenção de enfermidades que envolvem anemia e dispositivo para liberação local e sistêmica sustentada de uma composicão
UY26372A1 (es) &#34;imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen &#34;
BR0014441A (pt) Composições que apresentam estabilidade aperfeiçoada
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR0312960A (pt) Composição de comprimido de liberação sustentada de pramipexol
BRPI0411986A (pt) forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
BRPI0113539B8 (pt) processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia
BR0114100A (pt) Formulações de liberação controlada para administração oral
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
BR0308305A (pt) Fórmulas dosadas de liberação controlada
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
PE20040670A1 (es) Nuevas composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE: UCI-FARMA INDUSTRIA FARMACEUTICA LTDA

B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: ALTERADO DE: HOECHST MARION ROUSSEL, INC.

B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B25A Requested transfer of rights approved

Owner name: AVENTISUB II INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS HOLDINGS INC.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.063191/2012-53 ORIGEM: JUIZO DA 009A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0031919-18.2012.4.02.5101 ACAO ORDINARIA DE NULIDADE DA PATENTE AUTOR: EMS S/A REU: AVENTIS PHARMACEUTICALS INC. E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.063191/2012 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0031919-18.2012.4.02.5101 AUTOR: EMS S/A REU: AVENTISUB II INC. E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI DECISAO: ANTE AO EXPOSTO ACIMA, JULGO IMPROCEDENTE O PEDIDO DE NULIDADE DA PI 9812001-8, NA FORMA DO ARTIGO 487, I DO CPC. ADEMAIS, JULGO EXTINTO, SEM RESOLUCAO DO MERITO, COM BASE NO ART. 487, IV DO CPC, OS PEDIDOS DE ABSTENCAO DE ATO DE CONCORRENCIA DESLEAL E DE DECLARACAO DE NAO VIOLACAO DE DIREITO DE PROPRIEDADE INDUSTRIAL.

B25A Requested transfer of rights approved

Owner name: AVENTISUB HOLDINGS INC (US)

B25A Requested transfer of rights approved

Owner name: AVENTISUB INC (US)

B25D Requested change of name of applicant approved

Owner name: AVENTISUB LLC. (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/07/2018

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.063191/2012 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0031919-18.2012.4.02.5101 APELANTE: EMS S/A E OUTRO APELADO:AVENTISUB II INC. E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: DIANTE DO EXPOSTO, ACOLHO A DESISTENCIA DO RECURSO DE APELACAO DA AUTORA EMS S/A E NEGO PROVIMENTO A APELACAO DO INPI, PARA MANTER A SENTENCA QUE JULGOU IMPROCEDENTE O PEDIDO.